Qi Peng, Zhou Xiao-Yan, Du Xiang
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Mol Cancer. 2016 May 17;15(1):39. doi: 10.1186/s12943-016-0524-4.
Long non-coding RNAs (lncRNAs) comprise a diverse class of RNA transcripts >200 nucleotides in length with limited protein-coding potential. In addition to their possible role in cancer biology, circulating lncRNAs have emerged as a new class of promising cancer biomarkers, with independent studies demonstrating the feasibility of their use as tools in the diagnosis and prognosis of different types of malignancies and for predicting and possibly monitoring treatment response. However, critical issues are represented by nonuniform sample choice, handling and processing, blood cell contamination during sample preparation and the lack of consensus regarding data normalization. In this review, we discuss the value of circulating lncRNAs in the clinical setting, particularly with respect to their possible implementation as diagnostic and prognostic markers in cancer. Although the great potential of circulating lncRNAs as cancer biomarkers would be an important development in disease management, both intrinsic and extrinsic factors that may affect their measurement have not been fully characterized. Moreover, the clinical significance of circulating lncRNA may not be proven without a global consensus regarding procedures and standardized protocols for their detection.
长链非编码RNA（lncRNAs）是一类长度超过200个核苷酸、蛋白质编码潜力有限的多样RNA转录本。除了在癌症生物学中可能发挥的作用外，循环lncRNAs已成为一类新的有前景的癌症生物标志物，独立研究表明它们作为工具用于不同类型恶性肿瘤的诊断和预后以及预测和可能监测治疗反应是可行的。然而，关键问题包括样本选择、处理和加工不统一，样本制备过程中的血细胞污染以及数据标准化缺乏共识。在本综述中，我们讨论循环lncRNAs在临床环境中的价值，特别是它们作为癌症诊断和预后标志物的可能应用。尽管循环lncRNAs作为癌症生物标志物的巨大潜力将是疾病管理中的一项重要进展，但可能影响其测量的内在和外在因素尚未完全明确。此外，如果没有关于其检测程序和标准化方案的全球共识，循环lncRNA的临床意义可能无法得到证实。
Zotero 插件